Research programme: anti-CA9 vaccine - Dendreon

Drug Profile

Research programme: anti-CA9 vaccine - Dendreon

Latest Information Update: 28 Apr 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dendreon Corporation
  • Class Cancer vaccines
  • Mechanism of Action Carbonic anhydrase inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Cancer

Most Recent Events

  • 31 Dec 2013 Suspended - Preclinical for Cancer in USA (Parenteral)
  • 31 Dec 2011 Anti-CA9 vaccine is still in preclinical development for Cancer in USA
  • 28 Sep 2009 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top